Xbrane Biopharma
A biotechnology company specializing in the development of biosimilars.
XBRANE | ST
Overview
Corporate Details
- ISIN(s):
- SE0007789409 (+1 more)
- LEI:
- 5493008DKD05APTKQO39
- Country:
- Sweden
- Address:
- RETZIUS VÄG, 8, 171 65 Solna
- Website:
- https://xbrane.com/en/
- Sector:
- Manufacturing
Description
Xbrane Biopharma is a biotechnology company that specializes in the development of biosimilars—follow-on versions of approved biological drugs. The company's mission is to enhance the accessibility of biological treatments for serious diseases by creating more affordable alternatives. Xbrane utilizes a patented platform technology and efficient manufacturing systems, employing both bacterial and mammalian cells, to achieve lower production costs. Its development pipeline includes several biosimilar candidates, with a key product being a ranibizumab biosimilar.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2021-07-08 15:31 | English | 35.7 KB | |||
| 2021-06-30 23:01 |
Xbrane Biopharma has carried out a directed share issue raising gross proceeds …
|
English | 86.0 KB | ||
| 2021-06-30 23:01 |
Xbrane Biopharma har genomfört en riktad nyemission och tillförs därigenom 380 …
|
Swedish | 86.4 KB | ||
| 2021-06-30 12:00 |
CHANGE OF NUMBER OF SHARES AND VOTES IN XBRANE
|
English | 68.0 KB | ||
| 2021-06-30 12:00 |
FÖRÄNDRAT ANTAL AKTIER OCH RÖSTER I XBRANE
|
Swedish | 68.6 KB | ||
| 2021-06-27 22:40 |
Xlucane™ når det primära effektmåttet i den registreringsgrundande fas III stud…
|
Swedish | 77.2 KB | ||
| 2021-06-27 22:40 |
Xlucane™ meets the primary endpoint in the pivotal Phase III trial with Xlucane…
|
English | 77.7 KB | ||
| 2021-05-16 21:30 |
Xbrane announces ambition to generate positive operating cash flow monthly by l…
|
English | 74.8 KB | ||
| 2021-05-16 21:30 |
Xbrane uttalar ambition att generera positivt operationellt kassaflöde på månad…
|
Swedish | 76.6 KB | ||
| 2021-05-06 18:30 |
Announcement from Xbrane Biopharma's annual general meeting
|
English | 71.9 KB | ||
| 2021-05-06 18:30 |
Kommuniké från årsstämman i Xbrane Biopharma
|
Swedish | 73.4 KB | ||
| 2021-05-06 08:00 | Swedish | 721.4 KB | |||
| 2021-05-06 08:00 | English | 721.0 KB | |||
| 2021-03-30 20:00 |
Notice of annual general meeting in Xbrane Biopharma AB
|
English | 114.6 KB | ||
| 2021-03-30 20:00 |
Kallelse till årsstämma i Xbrane Biopharma AB
|
Swedish | 115.8 KB |
Automate Your Workflow. Get a real-time feed of all Xbrane Biopharma filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Xbrane Biopharma
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Xbrane Biopharma via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-01-17 | Karl Martin Erik Åmark | Other | Buy | 1,864,223 | 318,782.13 SEK |
| 2025-01-17 | Karl Martin Erik Åmark | Other | Sell | 1,864,223 | 315,053.69 SEK |
| 2025-01-16 | Siavash Bashiri | Other | Sell | 1,519,932 | 260,212.36 SEK |
| 2025-01-16 | Siavash Bashiri | Other | Buy | 1,500,000 | 256,500.00 SEK |
| 2023-09-12 | Karl Martin Erik Åmark | Other | Buy | 4,000 | 129,000.00 SEK |
| 2023-09-12 | Karl Martin Erik Åmark | Other | Sell | 4,000 | 128,200.00 SEK |
| 2023-09-11 | Karl Martin Erik Åmark | Other | Sell | 2,000 | 62,140.00 SEK |
| 2023-09-08 | Siavash Bashiri | Other | Sell | 5,890 | 194,959.00 SEK |
| 2023-09-08 | Karl Martin Erik Åmark | Other | Other | 4,320 | 968.54 SEK |
| 2023-09-08 | Karl Martin Erik Åmark | Other | Other | 4,320 | N/A |
Peer Companies
